CTRI/2021/08/035471已完成3 期
A Randomized, Multi-center, Active-controlled, Parallel group, Safety-assessor blind, Phase III,Comparative,Efficacy, Safety and Tolerability Study of Sugammadex Injection 100mg/ml manufactured by BDR Pharmaceuticals International Private Limited, India and Neostigmine Methylsulfate Injection 0.5mg/ml manufactured by Neon Laboratories Ltd., India in subjects scheduled for surgical procedure with Shallow Neuromuscular Blockade
BDR Pharmaceuticals Internationals Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and Female subjects of age group ââ?°Â¥18 to ââ?°Â¤65 years.
- •Subjects with American Society of Anesthesiologists (ASA) class I ââ?¬â??II
- •ASA ClassificationDefinitionAdult Examples, Including, but not Limited to:
- •ASA IA normal healthy subjectHealthy, non-smoking, no or minimal alcohol use
- •ASA IIA subject with mild systemic diseaseMild diseases only without substantive functional limitations. Examples include (but not limited to): current smoker, social alcohol drinker, obesity (30
- •Subjects scheduled for surgical procedures under general anesthesia (except cyclopropane or halothane anesthesia) with the use of succinylcholine for tracheal intubation and rocuronium for maintenance of shallow neuromuscular block.
- •Subjects with creatinine clearance ââ?°Â¥ 60 ml/min.
- •Subjects scheduled for surgical procedure in supine position.
- •Written informed consent from the patient, legally acceptable representative or parent and able to follow study procedures.
排除标准
- •Subjects who are not able to or not willing to sign an IRB/IEC approved consent form.
- •Subjects in whom a difficult intubation is expected because of anatomical malformations.
- •Subjects who are known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction.
- •Subjects who are known or suspected to have a personal or family history of malignant hyperthermia and skeletal muscle myopathies.
- •Subjects who are known or suspected to have an allergy or hypersensitivity to narcotics, muscle relaxants or other medication used during general anesthesia, bromide ion.
- •Subjects in the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury.
- •Subjects who are receiving prohibited medication as described in Appendix A in a dose and/or at a time point known to interfere with neuromuscular blocking agents such as antibiotics, anticonvulsants and Mg2+.
- •Subjects in whom the use of neostigmine and/or glycopyrrolate may be contraindicated such as subjects with mechanical obstruction of gastrointestinal or urinary tracts, peritonitis or doubtful bowel viability, use in conjunction with depolarising muscle relaxants such as suxamethonium.
- •Subjects with severe hepatic impairment with or without coagulopathy.
- •Subjects who are on anticoagulation therapy for a pre-existing or comorbid condition.
- •Subjects with pre-existing bradycardia, cardiac arrhythmia or recent coronary occlusion.
- •Subjects with history of epilepsy, vagotonia, hyperthyroidism, peptic ulceration or Parkinsonism.
- •Participation in any clinical study within 30 days before the administration of Investigational Product.
- •Subjects with positive serology for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human Immunodeficiency virus (HIV).
- •Subjects with suspected signs and symptoms of COVID-19 / confirmed novel coronavirus infection (COVID-19) or with a recent history of travel/contact with any COVID-19 positive subject/isolation/quarantine in last 14 days.
- •Pregnant or lactating women.
- •Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study, including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements
研究者
相似试验
尚未招募
不适用
A Multi-center, Randomized, Active-controlled, Parallel Design, Low-Intervention Clinical Trial; Pitavastatin Comparing with Atorvastatin in Patients with Pre-Diabetes Mellitus and Hypercholesterolemia for evaluate the New Onset Diabetes Mellitus (PIANO-DM study)Endocrine, nutritional and metabolic diseaseKCT0005394The Catholic University of Korea, Bucheon St. Mary's Hospital706
终止
不适用
Phase IV Clinical Trial to Evaluate in Children with Symptom Contral due to Persistent Allergic RhinitisDiseases of th respiratory systemKCT0000972Dong Hwa Pharm100
招募中
3 期
A clinical study to evaluate the efficacy and safety of Combination of Netarsudil and Latanoprost in Comparison with Latanoprost in Patients with Glaucoma or Eye HypertensioCTRI/2021/02/031337Sun Pharmaceutical Industries Limited
进行中（未招募）
1 期
Clinical study investigating efficacy and safety of BT524 in intra-operative use in patients undergoing major spine surgeryElective spine surgery with expected major blood lossMedDRA version: 20.0Level: PTClassification code 10051125Term: HypofibrinogenaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-001163-20-BEBiotest AG200
进行中（未招募）
1 期
Clinical study investigating efficacy and safety of BT524 in intra-operative use in patients undergoing major spinal or abdominal surgeryEUCTR2017-001163-20-DEBiotest AG220